Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

PHRD

Financiado

Cerrado

The development of Personalised Host Response Diagnostic kit

Drug resistance is a major reason for failure in cancer chemotherapy and/or modern targeted drugs. While tumours usually initially respond to therapy, resistance occurs within several cycles of treatments, or later on when patient... ver más

30/09/2018

TECHNION ISRAEL I...

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

TECHNION ISRAEL INSTITUTE OF TECHNOLOGY No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2018-09-30

ERC-PoC-2016: ERC-Proof of Concept-2016

I+D

Cerrada hace 8 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

TECHNION ISRAEL INSTITUTE O...

150.00K€ | Lider

SCATI LABS

403.26K€ | Participante

Proyectos interesantes

CROC

Medical Technol...

Data Science

176K€ Cerrado

DrugComb

Medical Technol...

Data Science

2M€ Cerrado

SENSITIVITYMARKERS

Medical Technol...

Data Science

71K€ Cerrado

3DTUMOUR

Medical Technol...

Data Science

150K€ Cerrado

TransPot

Medical Technol...

Data Science

3M€ Cerrado

NOSCAR

Medical Technol...

Data Science

305K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 18 meses Fecha Inicio: 2017-03-29
Fecha Fin: 2018-09-30

Líder del proyecto

TECHNION ISRAEL INSTITUTE OF TECHNOLOGY No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 150K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Drug resistance is a major reason for failure in cancer chemotherapy and/or modern targeted drugs. While tumours usually initially respond to therapy, resistance occurs within several cycles of treatments, or later on when patients are off therapy. Until recently, acquired and intrinsic resistance mechanisms for therapy were thought to be solely tumour driven. They are usually measured after tumours relapse or after several lines of treatments. However, in our ERC starting grant (HostResponse No. 260633), we found a novel way to predict resistance to therapy, already after 24 hours after the first drug administration. This discovery resulted in a new stream of research by means of published papers and the formation of special interest groups in cancer research and pharmaceutical disciplines that tackle this paradigm shift in cancer therapy. During our discussions with the cancer community, a clear need has emerged for a Specific Host-Driven Resistant Mechanisms (SHDRM®) diagnostic platform which will serve two (closely connected) markets:(1) the research community – enabling researchers to further examine this new paradigm; and (2) Clinicians- enabling oncologists to identify each patient specific host driven resistance mechanism and repurpose off-the-shelf drugs to counteract the specific factor driving the resistance. PHRD goal is to technically validate and develop a diagnostic platform Prototype for both markets including a clinical study design report which will enable to secure our partners including drug manufacturers, diagnostic providers, and the research community to commit to jointly push the new PHRD standard.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores